Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)

Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Oizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi MoritaKunihiko Kobayashi, Takeshi Isobe

研究成果査読

抄録

In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

本文言語English
ページ(範囲)823-824
ページ数2
ジャーナルInternational Journal of Clinical Oncology
27
4
DOI
出版ステータスPublished - 4月 2022

ASJC Scopus subject areas

  • 外科
  • 血液学
  • 腫瘍学

フィンガープリント

「Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B) (International Journal of Clinical Oncology, (2022), 27, 1, (112-120), 10.1007/s10147-021-02043-2)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル